Pharma
1 min read

BioNTech sign deal to co-develop OncoC4's cancer drug

The companies said they will co-develop the candidate, ONC-392, as a monotherapy or as a combination therapy in various cancer indications.

Reuters

Updated On Mar 20, 2023 at 06:10 PM IST

New Delhi: Germany's BioNTech SE said on Monday that it signed a deal with privately held OncoC4 Inc to co-develop and commercialize its cancer antibody drug candidate.

OncoC4 will get a $200 million upfront payment and is eligible to receive development, regulatory, and commercial milestone payments as well as double-digit tiered royalties.

The companies said they will co-develop the candidate, ONC-392, as a monotherapy or as a combination therapy in various cancer indications.

A late-stage trial for the drug has been planned for this year, the companies said.